Article
The relationship between paroxetine and the sparteine oxidation polymorphism.
Clinical pharmacology and therapeutics - 1 Mar 1992
Sindrup S H, Brøsen K, Gram L F, Hallas J, Skjelbo E, Allen A, Allen G D, Cooper S M, Mellows G, Tasker T C
Abstract excerpt
The relationship between the selective serotonin reuptake inhibitor paroxetine and the sparteine oxidation polymorphism was investigated in a combined single-dose (30 mg) and steady-state (30 mg/day for 2 weeks) study including a panel of nine extensive metabolizers and eight poor metabolizers of sparteine. The median area under the plasma concentration-time curve (AUC) after the first paroxetine dose was about...
Topics
- Adult
- Humans
- Oxidation-Reduction
- Paroxetine
- Phenotype
- Piperidines
- Polymorphism, Genetic
- Serotonin Antagonists
- Sparteine